Mevacor Daily OTC Switch Rejected Based On Patient Inability To Self Select

FDA joint committee finds that current system does not ensure appropriate patient self-selection for cholesterol-lowering therapy. Committee votes 20-3 against OTC marketing for Mevacor Daily. Behind-the-counter strategy for pharmacy urged.